PL330239A1 - Growt hormone constituent and bone reserption preventing factor in cyclic (coherent) treatment - Google Patents

Growt hormone constituent and bone reserption preventing factor in cyclic (coherent) treatment

Info

Publication number
PL330239A1
PL330239A1 PL97330239A PL33023997A PL330239A1 PL 330239 A1 PL330239 A1 PL 330239A1 PL 97330239 A PL97330239 A PL 97330239A PL 33023997 A PL33023997 A PL 33023997A PL 330239 A1 PL330239 A1 PL 330239A1
Authority
PL
Poland
Prior art keywords
reserption
growt
coherent
bone
cyclic
Prior art date
Application number
PL97330239A
Inventor
Erik Fink Eriksen
Anne-Marie Kappelgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL330239A1 publication Critical patent/PL330239A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL97330239A 1996-05-31 1997-05-29 Growt hormone constituent and bone reserption preventing factor in cyclic (coherent) treatment PL330239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK62396 1996-05-31

Publications (1)

Publication Number Publication Date
PL330239A1 true PL330239A1 (en) 1999-05-10

Family

ID=8095682

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97330239A PL330239A1 (en) 1996-05-31 1997-05-29 Growt hormone constituent and bone reserption preventing factor in cyclic (coherent) treatment

Country Status (14)

Country Link
EP (1) EP0907374A1 (en)
JP (1) JP2000512274A (en)
KR (1) KR20000016204A (en)
CN (1) CN1220609A (en)
AU (1) AU3025997A (en)
BR (1) BR9709499A (en)
CA (1) CA2257174A1 (en)
CZ (1) CZ383298A3 (en)
HU (1) HUP9904049A3 (en)
IL (1) IL126983A0 (en)
NO (1) NO985573L (en)
PL (1) PL330239A1 (en)
WO (1) WO1997046252A1 (en)
ZA (1) ZA974785B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (en) 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
JP4574849B2 (en) * 1998-06-09 2010-11-04 サファイア セラピューティクス,インコーポレイティド Method for preparing compounds having growth hormone releasing properties
US6784158B1 (en) 1998-06-09 2004-08-31 Novo Nordisk A/S Method for preparing a compound with growth hormone releasing properties
JP2001031635A (en) 1999-07-14 2001-02-06 Ajinomoto Co Inc Production of optically active n-protected-n-methyl- phenylalanine derivative
ES2333097T3 (en) 2000-05-31 2010-02-17 Raqualia Pharma Inc USE OF SECRETAGOGS OF GROWTH HORMONE TO STIMULATE GASTROINTESTINAL MOTILITY.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
BRPI0807046A2 (en) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Compound, pharmaceutical composition, methods of treating a disorder, cardiovascular disease and a patient suffering from reduced or dysfunctional gastrointestinal motility and, kit.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
ATE150648T1 (en) * 1990-11-26 1997-04-15 Robert R Recker TREATMENT OF OSTEOPOROSIS USING GROWTH HORMONE RELEASING FACTOR (GRF) IN CONJUNCTION WITH PARATHYROID HORMONE (PTH)
BR9407869A (en) * 1993-10-19 1996-10-29 Merck & Co Inc Combination of pharmaceutical composition and process for the treatment of osteoporosis

Also Published As

Publication number Publication date
KR20000016204A (en) 2000-03-25
CN1220609A (en) 1999-06-23
IL126983A0 (en) 1999-09-22
EP0907374A1 (en) 1999-04-14
AU3025997A (en) 1998-01-05
NO985573D0 (en) 1998-11-27
BR9709499A (en) 1999-08-10
WO1997046252A1 (en) 1997-12-11
HUP9904049A2 (en) 2000-04-28
HUP9904049A3 (en) 2000-07-28
ZA974785B (en) 1998-01-22
CA2257174A1 (en) 1997-12-11
NO985573L (en) 1999-01-29
JP2000512274A (en) 2000-09-19
CZ383298A3 (en) 1999-07-14

Similar Documents

Publication Publication Date Title
EP0767624A4 (en) Devices and methods for bone/tissue preparation
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
IL131543A0 (en) Cosmetic methods and compositions for preventing and treating chronological aging in human skin
ZA976598B (en) IGF-I and insulin formulation
IL125981A0 (en) Improved tissue destruction in cryosurgery
EP1047442A4 (en) Bone morphogenetic proteins and their use in bone growth
EP0955874A4 (en) Method and device for stable impedance plethysmography
ZA947138B (en) Skin care method and composition
PL332547A1 (en) Skin care compositions containing an acid and retinoide
HU9801511D0 (en) Human semaphorin-l (h-sema-l) and corresponding semaphorine in other species
GB2317182B (en) Sulfated polysaccharides and uses thereof in medical treatment
PL330239A1 (en) Growt hormone constituent and bone reserption preventing factor in cyclic (coherent) treatment
GB2325461B (en) Medical sharps and blades removal and containment structure
IL111554A (en) Methods and compositions for hair treatment
GB2317980B (en) Analogue multiplier using MOSFETs in nonsaturation region and current mirror
ZA971718B (en) Combination therapy to prevent bone loss-progesterone and estrogen agonists
GB9609944D0 (en) An improvement in the treatment of wastes
AU135003S (en) An abutment for use in dental implant
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
ZA947145B (en) Skin care method and composition
GB9614958D0 (en) Cosmetic skin treatment and apparatus therefor
GB9617346D0 (en) Therapeutic methods and compositions for use therein
GB2338231B (en) Medical sharps and blades removal and containment structure
GB9210405D0 (en) Improvements in and relating to surgical sutures
GB9620530D0 (en) Back and neck treatment device